Compare Recursion Pharmaceuticals Inc (RXRX) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Tencent Music Entertainment Group - ADR trades at $9 (market cap $15.08B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 9.9× Recursion Pharmaceuticals Inc's market cap, and Tencent Music Entertainment Group - ADR pays a 2.62% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | TME | |
|---|---|---|
Market Cap | $1.53B | $15.08B |
Sector | Health | Media |
52-Week High | $6.79 | $26.36 |
52-Week Low | $2.84 | $8.16 |
Enterprise Value | $946.50M | $11.85B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
TME trades at $8.94, down 1.97% for the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong 2025 revenue of $32.90B and net income of $11.06B, with a net income margin of 26.48%. Recent news highlights strategic moves like the Ximalaya acquisition and a partnership with Coca-Cola for the 2026 FIFA World Cup anthem.
The outlook is mixed; analyst consensus is a 'Hold' with a $14.00 price target, implying significant upside. Key opportunities include premium membership growth and ecosystem integration, while risks involve competition, user churn, and AI-related copyright issues. Cash flow trends show a projected recovery in 2026 after a negative 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
